Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Commentary

C-reactive Protein Apheresis in Acute Myocardial Infarction

Author(s): Maja Milosevic, Bela Balint, Ivan Ilic, Natasa Dukuljev and Petar Otasevic*

Volume 29, Issue 8, 2023

Published on: 22 March, 2023

Page: [555 - 558] Pages: 4

DOI: 10.2174/1381612829666230310090601

Price: $65

Next »
[1]
Buerke M, Sheriff A, Garlichs CD. CRP apheresis in acute myocardial infarction or COVID-19. Med Klin Intensivmed Notf Med 2022; 117(3): 191-9.
[http://dx.doi.org/10.1007/s00063-022-00911-x] [PMID: 35333926]
[2]
Sheriff A, Schindler R, Vogt B, et al. Selective apheresis of C-reactive protein: A new therapeutic option in myocardial infarction? J Clin Apher 2015; 30(1): 15-21.
[http://dx.doi.org/10.1002/jca.21344] [PMID: 25044559]
[3]
Ries W, Sheriff A, Heigl F, Zimmermann O, Garlichs CD, Torzewski J. “First in Man”: Case report of selective C-reactive protein apheresis in a patient with acute ST segment elevation myocardial infarction. Case Rep Cardiol 2018; 2018: 1-4.
[http://dx.doi.org/10.1155/2018/4767105] [PMID: 30533227]
[4]
Ries W, Heigl F, Garlichs C, Sheriff A, Torzewski J. Selective C‐reactive protein‐apheresis in patients. Ther Apher Dial 2019; 23(6): 570-4.
[http://dx.doi.org/10.1111/1744-9987.12804] [PMID: 30924312]
[5]
Boljevic D, Nikolic A, Rusovic S, Lakcevic J, Bojic M, Balint B. A promising innovative treatment for ST-elevation myocardial infarction: The use of C-reactive protein selective apheresis: Case report. Blood Purif 2020; 49(6): 753-7.
[http://dx.doi.org/10.1159/000506176] [PMID: 32114573]
[6]
Milosevic M, Balint B, Boskovic S, Bojic M, Nikolic A, Otasevic P. Early selective C-reactive protein apheresis in a patient with acute ST segment elevation myocardial reinfarction. Blood Purif 2021; 50(3): 399-401.
[http://dx.doi.org/10.1159/000510554] [PMID: 32998146]
[7]
Ries W, Torzewski J, Heigl F, et al. C-reactive protein apheresis as anti-inflammatory therapy in acute myocardial infarction: Results of the CAMI-1 study. Front Cardiovasc Med 2021; 8: 591714.
[http://dx.doi.org/10.3389/fcvm.2021.591714] [PMID: 33778017]
[8]
Anzai T. Inflammatory mechanisms of cardiovascular remodeling. Circ J 2018; 82(3): 629-35.
[http://dx.doi.org/10.1253/circj.CJ-18-0063] [PMID: 29415911]
[9]
Kayser S, Brunner P, Althaus K, Dorst J, Sheriff A. Selective apheresis of C-reactive protein for treatment of indications with elevated CRP concentrations. J Clin Med 2020; 9(9): 2947.
[http://dx.doi.org/10.3390/jcm9092947] [PMID: 32932587]
[10]
Sparkes BL, Woods K, Roth M, Welti R, Fleming SD. Phospholipase A2 alters membrane lipid composition during ischemia/reperfusion. The J Immunol 2009; 182 (1_Supplement): 39-55.
[http://dx.doi.org/10.4049/jimmunol.182.Supp.39.55] [PMID: 19109132]
[11]
Nijmeijer R, Lagrand WK, Baidoshvili A, et al. Secretory type II phospholipase A2 binds to ischemic myocardium during myocardial infarction in humans. Cardiovasc Res 2002; 53(1): 138-46.
[http://dx.doi.org/10.1016/S0008-6363(01)00480-1] [PMID: 11744022]
[12]
Nijmeijer R, Willemsen M, Meijer CJLM, et al. Type II secretory phospholipase A 2 binds to ischemic flip-flopped cardiomyocytes and subsequently induces cell death. Am J Physiol Heart Circ Physiol 2003; 285(5): H2218-24.
[http://dx.doi.org/10.1152/ajpheart.00887.2002] [PMID: 12805018]
[13]
Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon? Circulation 1999; 100(1): 96-102.
[http://dx.doi.org/10.1161/01.CIR.100.1.96] [PMID: 10393687]
[14]
Griselli M, Herbert J, Hutchinson WL, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med 1999; 190(12): 1733-40.
[http://dx.doi.org/10.1084/jem.190.12.1733] [PMID: 10601349]
[15]
Pepys MB, Hirschfield GM, Tennent GA, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006; 440(7088): 1217-21.
[http://dx.doi.org/10.1038/nature04672] [PMID: 16642000]
[16]
Radović M, Balint B, Tiška-Rudman L, Milenković L, Taseski J. Application of therapeutic plasma exchange in hematology. Transfus Sci 1994; 15(4): 481-5.
[http://dx.doi.org/10.1016/0955-3886(94)90182-1] [PMID: 10155567]
[17]
Balint B, Pavlovic M, Jevtic M, et al. Simple “closed-circuit” group-specific immunoadsorption system for ABO-incompatible kidney transplants. Transfus Apheresis Sci 2007; 36(3): 225-33.
[http://dx.doi.org/10.1016/j.transci.2006.11.004] [PMID: 17572153]
[18]
Balint B, Stepic N, Todorovic M, et al. Ibuprofen induced extensive toxic epidermal necrolysis – a single center experience with multidisciplinary therapeutic approach. Blood Transfus 2014; 12(3): 438-9.
[PMID: 25074525]
[19]
Torzewski J, Brunner P, Ries W, et al. Targeting C-reactive protein by selective apheresis in humans: Pros and cons. J Clin Med 2022; 11(7): 1771.
[http://dx.doi.org/10.3390/jcm11071771] [PMID: 35407379]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy